Eric Halioua
Algemeen Directeur bij PDC Line Pharma SASU
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Laurent Levy | M | - |
PDC Line Pharma SA
 PDC Line Pharma SA Pharmaceuticals: MajorHealth Technology Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua.
PDC Line Pharma SASU
 PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 10 jaar |
| Joel Plumas | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.
PDC Line Pharma SA
PDC Line Pharma SA Pharmaceuticals: MajorHealth Technology Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua. | 10 jaar |
| Etienne Marc Sokal | M | - |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 15 jaar |
| Mondher Mahjoubi | M | 65 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
| Eduardo Bravo Fernández de Araoz | M | 58 |
European Biopharmaceutical Enterprises
 European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
| François Fontaine | M | - |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.
PDC Line Pharma SA
PDC Line Pharma SA Pharmaceuticals: MajorHealth Technology Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua. | - |
| Christophe Jean | M | 67 |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
| Amel Tounsi | M | 43 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
| Sangwoo Lee | M | 52 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | 5 jaar |
| Alain Herrera | M | 74 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
| Alain Aragues | M | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
| Jean-Paul Prieels | M | 78 |
PDC Line Pharma SASU
PDC Line Pharma SASU Pharmaceuticals: MajorHealth Technology PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France. | - |
| Jean-Thomas Vilquin | M | - |
MYOSIX SA
 MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | 24 jaar |
| Hervé Eloi Dominique Brailly | M | 62 |
BioCuster
| - |
| Piers John Morgan | M | 57 |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
| Marcio Scorsin | M | - |
MYOSIX SA
MYOSIX SA BiotechnologyHealth Technology MYOSIX SA develops cell-based therapeutics. The company is involved in the development of autologous cell therapy products for the treatment of cardiopathies and certain forms of myopathy in humans. MYOSIX specializes in the development of cell-based therapeutics against other pathologies like cancers. MYOSIX is also engaged in a number of R&D projects and develops a cell and tissue bank for therapeutic or R&D purposes. The company was founded by Vilquin, Marolleau, Scorsin, Eisenmann and Halioua in 2000 and is headquartered in Saint-Germain-en-Laye, France. | 24 jaar |
| Barbara Freischem | F | - |
European Biopharmaceutical Enterprises
European Biopharmaceutical Enterprises BiotechnologyHealth Technology European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| John Tchelingerian | M | - |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 5 jaar |
| Carole Monterrat | M | - |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 5 jaar |
| Frank Hazevoets | M | 57 |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 4 jaar |
| Béatrice de Vos | M | - |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 4 jaar |
| Eddy Rommel | M | - |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | 3 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| België | 14 | 63.64% |
| Frankrijk | 11 | 50.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Eric Halioua
- Persoonlijk netwerk
